 |
0 Diseases |  |
12 Trials |
|
12 Trials |  |
337 News |  |
| «1234567 |
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Enrollment open, Surgery, Metastases: CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - May 15, 2013
P=N/A, N=13, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Not yet recruiting --> Recruiting
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
New P1 trial, Metastases: CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 23, 2013
P1, N=13, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Enrollment open, Combination therapy, Metastases: CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 21, 2013
P1, N=15, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
New P1 trial, Combination therapy, Metastases: CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 16, 2013
P1, N=15, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
- ||||| Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
New P2 trial: Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients (clinicaltrials.gov) - Apr 14, 2013
P2, N=100, Recruiting, Sponsor: Cornerstone Pharmaceuticals, Inc.
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
New P2 trial, Combination therapy, Metastases: Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 10, 2013
P2, N=0, Withdrawn, Sponsor: Cornerstone Pharmaceuticals, Inc.
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Enrollment change, Surgery, Metastases: CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Jan 23, 2013
P=N/A, N=13, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Not yet recruiting --> Recruiting N=10 --> 13
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Enrollment open: CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 15, 2013
P1, N=20, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
N=10 --> 13 Not yet recruiting --> Recruiting
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
New P1 trial: CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 14, 2013
P1, N=20, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Enrollment closed, Metastases: Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies (clinicaltrials.gov) - Nov 12, 2012
P1, N=20, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
New P2 trial: Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome (clinicaltrials.gov) - Jan 26, 2012
P2, N=30, Not yet recruiting, Sponsor: Cornerstone Pharmaceuticals, Inc.
- | Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Enrollment closed, Metastases: A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies (clinicaltrials.gov) - Jan 22, 2012
P1/2, N=40, Active, not recruiting, Sponsor: Cornerstone Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Bylantra (devimistat) / Cornerstone Pharma
Enrollment closed, Combination therapy: A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients (clinicaltrials.gov) - Sep 13, 2011
P1/2, N=60, Active, not recruiting, Sponsor: Cornerstone Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting